NATCO announces launch of breast cancer medicine Lapatinib Tablets in the U.S.

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing partner, Lupin Limited (Lupin), has launched Lapatinib Tablets, 250 mg, in the United States market after NATCO received the final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Federal Drug Administration (USFDA). NATCO was the 1st ANDA applicant for Lapatinib Tablets, 250mg, containing a Paragraph IV certification. Lapatinib Tablets, 250mg, is sold under Brand name TYKERB®, of Novartis Pharmaceuticals Corporation (Novartis), which is indicated primarily for the treatment of certain types of breast cancer. For the 12 months ending June, 2020, TYKERB® had sales of approximately USO 61 million in the U.S. (IQVIA MAT June 2020).

The release as fetched from its publisher. natcopharma.co.in ↗